Merck sues the Biden Administration over the Medicare drug price negotiation program in the Inflation Reduction Act. Some hospitals’ outpatient clinics could face challenges prescribing 340B drugs following the removal of COVID-era guidance. And, a new study finds that insurance coverage of expensive new drugs like Ozempic does not guarantee adherence. That’s coming up on today’s episode of Gist Healthcare Daily.
Hosted on Acast. See acast.com/privacy for more information.
